Table 2.
Results of the subgroup analysis
| SUBGROUPS | STUDIES | P VALUE | HETEROGENEITY (I2) |
|---|---|---|---|
| Diagnosis: OUDg/SUDa/People who smoke/other | 4/9/2/2 | 0.002 / 0.41 / 0.55 / 0.96 | 95% / 88% / 59% / 47% |
|
Sex ratio: More women/more men/both |
3/9/5 | 0.19 / 0.0009/ < 0.0001 | 87% / 93% / 0% |
|
Treatment settings: residential/outpatient |
6/11 | 0.43 / 0.001 | 93% / 91% |
|
Dose: < 8 weeks/ 8 weeks or more |
6/11 | 0.74 / 0.0004 | 90% / 92% |
| MBI: MBRPb/MBSRd/app/MOREe/other | 5/6/1/2/3 | 0.006/ 0.002 / 0.07 / 0.96 / 0.44 | 73% / 95% / NA / 47% / 93% |
|
Control: active/no active control |
11/6 | 0.17 / 0.006 | 88% / 95% |
|
Blinding: Double/Patient/Researcher/Open label |
0/2/4/11 | NA/0.05/0.80/0.0002 | NA/0%/93%/92% |
aSUD: Substance Use Disorder, bMBRP: Mindfulness Based Relapse Prevention, cPACS: Penn Alcohol Craving Scale, dMBSR: Mindfulness Based Stress Reduction, eMORE: Mindfulness Oriented Recovery Enhancement, fVAS: Visual Analog Scale, gOUD: Opioid Use Disorder, hHCQ: Heroin Craving Questionnaire